4-(NITROOXY)BUTYL (2S)-2-(6-METHOXY-2-NAPHTHYL)PROPANOATE

• CAT Number: M034086
• CAS Number: 163133-43-5
• Molecular Formula: C18H21NO6
• Molecular Weight: 347.367
• Purity: ≥95%
• Target: COX
• Storage: Store at +4C
• IUPAC Name: 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
• InChI: InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1
• InChIKey: AKFJWRDCWYYTIG-ZDUSSCGKSA-N
• SMILES: CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCO[N+](=O)[O-]

4-(Nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl)propanoate（Cat No.:M034086）, is a chemical compound with a complex structure. It consists of a (2S)-2-(6-methoxy-2-naphthyl)propanoate moiety connected to a 4-(nitrooxy)butyl group. This compound’s structure signifies its potential application in organic synthesis, especially in the creation of complex molecules. The specific arrangement of functional groups offers opportunities for diverse reactivity and could make it valuable in the development of specialized compounds for applications such as pharmaceuticals, materials, or research purposes. The presence of a nitrooxy group and the naphthyl structure introduces the potential for specific interactions and reactivity.

Reference

1: Miglietta D, De Palma C, Sciorati C, Vergani B, Pisa V, Villa A, Ongini E, Clementi E. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy. Orphanet J Rare Dis. 2015 Aug 22;10:101. doi: 10.1186/s13023-015-0311-0. PubMed PMID: 26296873; PubMed Central PMCID: PMC4546261. 2: Li X, Zhang J, Bao Y, Ye Y, Li W, Yin W, Guo F, Chen A. WITHDRAWN: Efficacy and safety of short-term treatment of naproxcinod in patients with osteoarthritis (OA) of the hip: A prospective, randomized study. Arch Gerontol Geriatr. 2015 Jan 31. pii: S0167-4943(15)00013-8. doi: 10.1016/j.archger.2015.01.012. [Epub ahead of print] PubMed PMID: 25912890. 3: Shi X, Shang W, Wang S, Xue N, Hao Y, Wang Y, Sun M, Du Y, Cao D, Zhang K, Shi Q. Simultaneous quantification of naproxcinod and its active metabolite naproxen in rat plasma using LC-MS/MS: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:157-62. doi: 10.1016/j.jchromb.2014.12.001. Epub 2014 Dec 11. PubMed PMID: 25550191. 4: Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, Miller BK, Gordish-Dressman H, Ongini E, Miglietta D, Nagaraju K. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49. doi: 10.1093/hmg/ddu033. Epub 2014 Jan 23. PubMed PMID: 24463621; PubMed Central PMCID: PMC4030778. 5: Inugala UR, Pothuraju NR, Vangala RR. Quality by design approach for the separation of naproxcinod and its related substances by fused core particle technology column. J Chromatogr Sci. 2013 May-Jun;51(5):453-9. doi: 10.1093/chromsci/bms162. Epub 2012 Oct 11. PubMed PMID: 23060406. 6: Naproxcinod. Prescrire Int. 2012 Jul;21(129):180. PubMed PMID: 22852285. 7: Townsend R, Bittar N, Rosen J, Smith W, Ramsay A, Chrysant SG, Weiss R, Pivodic A, Duquesroix B, Djian J. Blood pressure effects of naproxcinod in hypertensive patients. J Clin Hypertens (Greenwich). 2011 May;13(5):376-84. doi: 10.1111/j.1751-7176.2010.00419.x. Epub 2011 Jan 25. PubMed PMID: 21545399. 8: Zhang K, Xue N, Yuan Z, Li L, Shi X, Cao L, Du Y. Separation of the two enantiomers of naproxcinod by chiral normal-phase liquid chromatography. J Chromatogr Sci. 2011 Apr;49(4):272-5. PubMed PMID: 21439116. 9: White WB, Schnitzer TJ, Bakris GL, Frayssinet H, Duquesroix B, Weber M. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 1;107(9):1338-45. doi: 10.1016/j.amjcard.2010.12.046. Epub 2011 Mar 2. PubMed PMID: 21371681. 10: Björnsson MA, Simonsson US. Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration. Br J Clin Pharmacol. 2011 Jun;71(6):899-906. doi: 10.1111/j.1365-2125.2011.03924.x. PubMed PMID: 21272053; PubMed Central PMCID: PMC3099376. 11: Schnitzer TJ, Hochberg MC, Marrero CE, Duquesroix B, Frayssinet H, Beekman M. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthritis Rheum. 2011 Feb;40(4):285-97. doi: 10.1016/j.semarthrit.2010.06.002. Epub 2010 Sep 9. PubMed PMID: 20828790. 12: Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum. 2010 Dec;62(12):3635-44. doi: 10.1002/art.27694. PubMed PMID: 20722026. 13: Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage. 2010 May;18(5):629-39. doi: 10.1016/j.joca.2009.12.013. Epub 2010 Feb 16. PubMed PMID: 20202489. 14: White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009 Sep 15;104(6):840-5. doi: 10.1016/j.amjcard.2009.05.014. PubMed PMID: 19733721. 15: Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol. 2009 Jun;36(6):1290-7. doi: 10.3899/jrheum.081011. Epub 2009 May 1. PubMed PMID: 19411388. 16: Geusens P. Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57. doi: 10.1517/14712590902926071 . Review. PubMed PMID: 19392579. 17: Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen, NO-naproxen. Drugs R D. 2007;8(4):255-8. Review. PubMed PMID: 17596112.